p53 expression in hepatocellular carcinoma in Greece: Correlation with epidemiological and histopathological data

Pathology Research and Practice

Volumn 192, Issue 11, 1996, Pages 1100-1106

  Skopelitou, A ^a,d   Hadjiyannakis, M ^b   Alexopoulou, V ^c   Kamina, S ^a   Krikoni, O ^a   Agnantis, N J ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

^b Asklepeion General Hospital   (Greece)

^c Volos General Hospital   (Greece)

^d NONE   (Greece)

Author keywords

Cirrhosis; HBV; HCV; Hepatocellular carcinoma; p53; Viral hepatitis

Indexed keywords

MONOCLONAL ANTIBODY; ONCOPROTEIN; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER GRADING; CORRELATION FUNCTION; DYSPLASIA; FEMALE; GENE EXPRESSION; GREECE; HEPATITIS B; HEPATITIS C; HEPATITIS NON A NON B; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOPEROXIDASE STAINING; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; TUMOR SUPPRESSOR GENE;

EID: 0030498719     PISSN: 03440338     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0344-0338(96)80026-4     Document Type: Article

References (48)

1. Bartek J, Bartkova J, Vojtesek B, Staskova Z, Lukas J, Rejthar A, Kovarik J, Midgley CA, Cannon JV, Lane DP (1991) Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene 6: 1699-1703
2. Beasley RP (1982) Hepatitis B virus as the etiologic agent in hepatocellular carcinoma-epidemiologic considerations. Hepatology 2: 21-26
3. Bishop JM (1987) The molecular genetics of cancer. Science 235: 305-311
4. Bishop JM (1983) Cellular oncogenes and retroviruses. Ann Rev Biochem 52: 301-354
5. Bressac B, Kew M, Wands J, Ozturk M (1991) Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 350: 429-431
6. Chang K, Ding I, Kern FG (1991) Immunohistochemical analysis of p53 and HER-2/neu proteins in human tumors. J Histochem Cytochem 39: 1281-1289
7. Challen C, Lunec J, Warren W, Collier J, Bassendine MF (1992) Analysis of the p53 tumor-suppressor gene in hepatocellular carcinomas from Britain. Hepatology 26: 1362-1366
8. Cohen C, DeRose P (1994) Immunohistochemical p53 in hepatocellular carcinoma and liver cell dysplasia. Modern Pathology 7: 536-539
9. Collier JD, Carpenter M, Burt AD, Bassendine MF (1994) Expression of mutant p53 protein in hepatocellular carcinoma. Gut 35: 98-100
10. Dalekos GN, Zervou E, Karabini F, Tsianos EV (1995) Prevalence of viral markers among refugees from southern Albania: increased incidence of infection with hepatitis A, B and D viruses. Europ J Gastroenterol Hepatol 7: 553-558
11. Deppert W, Buschhausen-Denker G, Patschinsky T, Steinmeyer K (1990) Cell cycle control of p53 in normal (3T3) and chemically transformed (Meth A) mouse cells. Requirement for cell cycle progression. Oncogene 5: 1701-1706
12. Edmondsen HA, Steiner PE (1954) Primary carcinoma of the liver: a study of 100 cases among 48.900 necropsies. Canser (Phila) 7: 462-503
13. Fausto N, Shank PR (1983) Oncogene expression in liver regeneration and hepatocarcinogenesis. Hepatology 3: 1016-1023
14. Finlay CA, Hinds PW, Levine AJ (1989) The p53 protooncogene can act as a suppressor of transformation. Cell 57: 1083-1093
15. Finlay CA, Hinds PW, Tan TH, Levine AJ (1988) Activating mutations for transformation by p53 produce a gene product that forms as hsc-70-p53 complex with an altered half-life. Mol Cell Biol 8: 531-539
16. Fujimori M, Tokino T, Hino O, Kitagawa T, Imamura T, Okamoto E, Mitsunobu E, Ishikawa T, Nakagama H, Harada H, Yagura M, Matsubara K, Nakamura Y (1991) Allelotype study of primary hepatocellular carcinoma. Cancer Res 51: 89-93
17. Goldblum JR, Bartos RE, Carr KA, Frank TS (1993) Hepatitis B and alterations of the p53 tumor suppressor gene in hepatocellular carcinoma. Am J Surg Pathol 17; 1244-1251
18. Hadziyannis SJ, Hatzakis A, Papaioannou C, Anastasakos C, Vassiliadis E (1987) Endemic hepatitis delta virus infection in a Greek community. In: Rizzetto M, Gerin JL, Purcell RH (Eds) The Hepatitis Delta Virus and its infection, pp 181-202., New York
19. Hollstein M, Sidransky D, Vogelstein B, Harris CC (1991) P53 mutations in human cancer. Science 253: 49-53
20. Hsia CC, Kleiner DE, Axiotis CA, Di Bisceglie A, Nomura AMY, Stemmermann GN, Tabor E (1992) Mutations of p53 gene in hepatocellular carcinoma: roles of hepatitis B virus and aflatoxin contamination in the diet. J Natl Cancer Inst 84: 1638-1641
21. Hsu IC, Metcalf RA, Sun T, Welsh JA, Wang NJ, Harris CC (1991) Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 350: 427-428
22. Iggo R, Gather K, Bartek J, Lane D, Harris AL (1990) Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 335: 675-679
23. Isobe M, Emanuel BS, Givol D (1986) Localization of gene for human p53 tumour antigen to bind 17p13. Nature 320: 84-85
24. Köshy R, Zahm P, Wollersheim M, Hofschneider M (1989) Transactivation by HBV x gene product. In: Bannasch PD, Keppler G, Weber (Eds) Liver cell carcinoma, pp 117-133. Kluwer Academic Publ., Dordrecht, Boston, London
25. Kress S, Jahn UR, Buchmann A, Bannasch P, Schwartz M (1992) p53 mutations in human hepatocellular carcinomas from Germany. Cancer Res 52: 3220-3223
26. Laurent-Puig P, Flejou JF, Fabre M, Bedossa P, Belghiti J, Gayral F, Franco D (1992) Overexpression of p53: a rare event in a large series of white patients with hepatocellular carcinoma. Hepatology 16: 1171-1175
27. Mercer WE, Avignolo C, Baserga R (1984) Role of the p53 protein in cell proliferation as studied by micro injection of monoclonal antibodies. Mol Cell Biol 4: 276-282
28. Murakami Y, Hayashi K, Hirohashi S, Sekiya T (1991) Aberrations of tumor suppressor p53 and retinoblastoma genes in human hepatocellular carcinomas. Cancer Res 51: 5520-5525
29. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, Bigner SH, Davidson N, Baylin S, Devilee P, Glover T, Collins FS, Weston A, Modali R, Harris CC, Vogelstein B (1989) Mutations of the p53 gene occur in diverse human tumor types. Nature 342: 705-708
30. Oda T, Tsuda H, Scarpa A, Sakamoto M, Hirohashi S (1992) p53 gene mutation spectrum in hepatocellular carcinoma. Cancer Res 52: 6358-6364
31. Ozturk M, Collaborators (1991) p53 mutation in hepatocellular carcinoma after aflotoxin exposure. Lancet 338: 1356-1359
32. Papaevangelou G, Kyriakidou A, Vissoulis L, Trichopoulos D (1976) Seroepidemiological study of HBV infections in Athens, Greece. J Hyg Camb 76: 229-234
33. Porter P, Gown A, Kramp S, Coltera M (1992) Widespread p53 overexpression in human malignant tumours. Am J Pathol 140: 145-153
34. Reich NC, Levine AJ (1984) Growth regulation of a cellular tumour antigen p53, in nontransformed cells. Nature 308: 199-201
35. Shafritz DA and Hadjiyannis SJ (1986) Molecular pathophysiology of persistent hepatitis B virus infection in relation to chronic liver disease and primary hepatocellular carcinoma. In: Farber, E, Phillips, MJ and Kaufman, N (Eds) Pathogenesis of Liver Diseases, pp 136-152. William and Wilkins CO, Baltimore
36. Simon D, Knowles BB, Weith A (1991) Abnormalities of chromosome 1 and loss of heterozygosity of 1p in primary hepatomas. Oncogene 6: 765-770
37. Slagle BL, Zhou Yi-Z, Butel JS (1991) Hepatitis B virus integration event in human chromosome 17p near the p53 gene identifies the region of the chromosome commonly deleted in virus-positive hepatocellular carcinomas. Cancer Res 51: 49-54
38. Spandidos DA (1986) A unified theory for the development of cancer. Biosci Rep 6: 691-708
39. Tanaka S, Toh Y, Adachi E, Matsumata T, Mori R, Sugimachi K (1993) Tumor progression in hepatocellular carcinoma may be mediated by p53 mutation. Cancer Res 53: 2884-2887
40. Terada T, Shimizu K, Izumi R, Nakanuma Y (1994) p53 expression in formalin-fixed, paraffin-embedded archival specimens of intrahepatic cholangiocarcinoma: retrieval of p53 antigenicity by microwave oven heating of tissue sections. Modern Pathology 7: 249-252
41. Tsuda H, Zhang W, Shimosato Y, Yokoto J, Terada M, Sugimura T, Miyamura T, Hirohashi S (1990) Allele loss on chromosome 16 associated with progression of human hepatocellular carcinoma. Proc Natl Acad Sci USA 87: 6791-6794
42. Volkmann M, Hofmann WJ, Muller M, Raeth U, Otto G, Zentgraf H, Galle PR (1994) P53 overexpression is frequent in European hepatocellular carcinoma and largely independent of the codon 249 hot spot mutation. Oncogene 9: 195-204
43. Walker GJ, Hayward NK, Falvey S, Cooksley WG (1991) Loss of somatic heterogygosity in hepatocellular carcinoma. Cancer Res 51: 4367-4370
44. Zhang WD, Hirohashi S, Tsuda H, Shimosato Y, Yokoto J, Terada M, Sugimura T (1990) Frequent loss of heterozygosity of chromosomes 16 and 4 in human hepatocellular carcinoma. Jpn J Cancer Res 81: 108-111
45. Qiao L, Wu P, Chaleb AH, Pizzolo JG, Miller TB, Melamed MR (1994) Bivariate flow cytometric analysis of p53 and DNA content in hepatocellular carcinoma. Anal Quant Cytol Histol 16: 124-130
46. Kamel D, Soini I, Uyorva K, Khalifa A, Maujout A, Vahakanjas K, Paakko P (1994) Immunohistochemical analysis of p53 protein overexpression in liver cell dysplasia and in hepatocellular carcinoma. Virchows Archiv 424: 613-621
47. Schaff ZS, Sarosi I, Hsia CC, Kiss A, Tabor E (1995) p53 in Malignant and Benign Liver Lesions. Eur J Cancer 31A: 1847-1850
48. Linden MD, Nathanson SD, Zarbo RJ (1995) Evaluation of anti-p53 Antibody Staining Immunoreactivity in Benign Tumors and Nonneoplastic Tissues. Appl Immunohistochem 3: 232-238